Search

Your search keyword '"Sledge G"' showing total 380 results

Search Constraints

Start Over You searched for: Author "Sledge G" Remove constraint Author: "Sledge G"
380 results on '"Sledge G"'

Search Results

1. Phase III trial of short-course radiotherapy followed by CAPOXIRI versus CAPOX in locally advanced rectal cancer: the ENSEMBLE trial

2. 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)

3. 215P Impact of HER2 low on survival in patients treated with standard therapies in advanced breast cancer

4. 273TiP ACE-Breast-03: A phase II study patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens treated with ARX788

5. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

10. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

11. Research needs in breast cancer

12. 1st International consensus guidelines for advanced breast cancer (ABC 1)

13. MONARCH 2: subgroup analysis of patients receiving abemaciclib+fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer (ABC)

14. MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2(-)-Advanced Breast Cancer

15. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy

19. 45O Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2

31. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years

32. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

33. Corrigendum to '3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)' [Breast 31 (February 2017) 244-259]

35. Correction to: 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

36. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)' [Breast 31 (February 2017) 244-259]

39. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials

40. 2. Survival Impact of HER-2/Neu, Cox-2, Urokinase Plasminogen Activator (upa), Cytokeratin 17/5,6 and other Markers with Long-Term Outcome of Early Breast Cancer. Report from the British Columbia Tissue Micro-Array Project (BCTMAP)

42. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials

43. 5BA Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry

45. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

46. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

48. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

50. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Catalog

Books, media, physical & digital resources